KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Return on Equity (2016 - 2025)

Historic Return on Equity for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to 0.0%.

  • Travere Therapeutics' Return on Equity fell 3300.0% to 0.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.0%, marking a year-over-year decrease of 3300.0%. This contributed to the annual value of 0.01% for FY2024, which is 21800.0% down from last year.
  • As of Q3 2025, Travere Therapeutics' Return on Equity stood at 0.0%, which was down 3300.0% from 0.0% recorded in Q2 2025.
  • Travere Therapeutics' 5-year Return on Equity high stood at 5.32% for Q2 2024, and its period low was 0.78% during Q3 2021.
  • Its 5-year average for Return on Equity is 0.37%, with a median of 0.0% in 2025.
  • As far as peak fluctuations go, Travere Therapeutics' Return on Equity surged by 49300bps in 2024, and later crashed by -53300bps in 2025.
  • Over the past 5 years, Travere Therapeutics' Return on Equity (Quarter) stood at 0.71% in 2021, then surged by 204bps to 0.74% in 2022, then skyrocketed by 49bps to 1.1% in 2023, then plummeted by -106bps to 0.07% in 2024, then surged by 100bps to 0.0% in 2025.
  • Its Return on Equity was 0.0% in Q3 2025, compared to 0.0% in Q2 2025 and 0.02% in Q1 2025.